Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The MACRO-2 trial

被引：1

作者：

Aranda, E. ^{[1
]}

Ia-Alfonso, P. Garc ' ^{[2
]}

Benavides, M. ^{[3
]}

Sanchez-Ruiz, A. ^{[4
]}

Guillen-Ponce, C. ^{[5
]}

Safont, M. J. ^{[6
]}

Alcaide, J. ^{[7
]}

Gomez, A. ^{[1
]}

Lopez, R. ^{[8
]}

Manzano, J. L. ^{[9
]}

Mendez-Urena, M. ^{[10
]}

Lopez, C. ^{[11
]}

Garcia-Paredes, B. ^{[12
,13
]}

Gravalos, C. ^{[14
]}

Garcia-Garcia, T. ^{[15
]}

Falco, E. ^{[16
]}

Martin-Valades, J. I. ^{[17
]}

Gonzalez-Flores, E. ^{[18
]}

Navalon, M. ^{[19
]}

Diaz-Rubio, E. ^{[12
,13
]}

机构：

[1] Univ Cordoba, Maimonides Inst Biomed Res IMIBIC, Reina Sofia Hosp,Med Oncol, Spanish Canc Network RTICC,Inst Salud Carlos III, Cordoba, Spain

[2] Gregorio Maranon Hosp, Med Oncol, Madrid, Spain

[3] Hosp Univ Reg & Virgen de la Victoria, Med Oncol, Malaga, Spain

[4] Puerta de Hierro Hosp, Med Oncol, Madrid, Spain

[5] Univ Ramon & Cajal Hosp, Med Oncol, Madrid, Spain

[6] Univ Gen Hosp, Med Oncol, Valencia, Spain

[7] Costa del Sol Hosp, Med Oncol, Malaga, Spain

[8] Hosp Clin Santiago, Med Oncol, Santiago De Compostela, Spain

[9] Germans Trias & Pujol Hosp ICO, Med Oncol, Badalona, Spain

[10] Hosp Mostoles, Med Oncol, Mostoles, Spain

[11] Marques de Valdecilla Hosp, Med Oncol, Santander, Spain

[12] HC San Carlos, Madrid, Spain

[13] Inst Carlos III, Spanish Minist Sci & Innovat, Med Madrid, Ctr Affiliated Red Temat Invest Cooperat RD06 002, Madrid, Spain

[14] Doce Octubre Hosp, Med Oncol, Madrid, Spain

[15] Morales Meseguer Hosp, Med Oncol, Murcia, Spain

[16] Son Llatzer Hosp, Med Oncol, Palma De Mallorca, Spain

[17] Fdn Jimenez Diaz, Med Oncol, E-28040 Madrid, Spain

[18] Virgen de las Nieves Hosp, Med Oncol, Granada, Spain

[19] Complejo Asistencial, Med Oncol, Zamora, Spain

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31044-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2122

引用

页码：S371 / S372

页数：2

共 50 条

[41] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial.
Kasper, Stefan
Meiler, Johannes
Knipp, Heike
Hoehler, Thomas
Reimer, Peter
Steinmetz, Tilman
Berger, Winfried
Linden, Gabriele
Ting, Saskia
Markus, Peter
Paul, Andreas
Schuler, Martin H.
Trarbach, Tanja
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[42] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - Primary endpoint analysis of the CEBIFOX trial
Kasper, S.
Meiler, J.
Knipp, H.
Hoehler, T.
Reimer, P.
Steinmetz, T.
Berger, W.
Linden, G.
Ting, S.
Markus, P.
Paul, A.
Dechene, A.
Kostbade, K.
Schuler, M.
Trarbach, T.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 99 - 100
[43] RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial
Normanno, N.
Abate, R. Esposito
Lambiase, M.
Forgione, L.
Cardone, C.
Iannaccone, A.
Sacco, A.
Rachiglio, A. M.
Martinelli, E.
Rizzi, D.
Pisconti, S.
Biglietto, M.
Bordonaro, R.
Troiani, T.
Latiano, T. P.
Giuliani, F.
Leo, S.
Rinaldi, A.
Maiello, E.
Ciardiello, F.
ANNALS OF ONCOLOGY, 2018, 29 (01) : 112 - 118
[44] Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
Bokemeyer, C.
Bondarenko, I.
Hartmann, J. T.
de Braud, F.
Schuch, G.
Zubel, A.
Celik, I.
Schlichting, M.
Koralewski, P.
ANNALS OF ONCOLOGY, 2011, 22 (07) : 1535 - 1546
[45] Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
Tabernero, Josep
Van Cutsem, Eric
Diaz-Rubio, Eduardo
Cervantes, Andres
Humblet, Yves
Andre, Thierry
Van Laethem, Jean-Luc
Soulie, Patrick
Casado, Esther
Verslype, Chris
Valera, Javier Sastre
Tortora, Giampaolo
Ciardiello, Fortunato
Kisker, Oliver
de Gramont, Aimery
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5225 - 5232
[46] Triplet chemotherapy plus cetuximab as first -line treatment in RAS wild -type metastatic colorectal carcinoma patients
Samalin, E.
Mazard, T.
Assenat, E.
Rouyer, M.
De la Fouchardiere, C.
Guimbaud, R.
Smith, D.
Portales, F.
Ychou, M.
Fiess, C.
de Forges, H.
Lopez-Crapez, E.
Thezenas, S.
ANNALS OF ONCOLOGY, 2019, 30
[47] Cetuximab plus capecitabine plus irinotecan (CCI) versus cetuximab plus capecitabine plus oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study Group.
Heinemann, V.
Von Weikersthal, L. Fischer
Moosmann, N.
Vehling-Kaiser, U.
Stauch, M.
Oruzio, D.
Schulze, M.
Walther, J.
Weiss, J.
Dietzfelbinger, H.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 158S - 158S
[48] Efficacy and safety of cetuximab plus raltitrexed as first-line maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): An interim analysis of a multi-center phase II trial
Li, S.
Zhu, L.
Zhao, M.
Xu, J.
Jiang, H.
Zhong, X.
Xu, S.
Shen, H.
Qiao, L.
ANNALS OF ONCOLOGY, 2024, 35 : S1436 - S1436
[49] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB plus MFOLFOX OVER BEVACIZUMAB plus MFOLFOX AS A FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER PATIENTS WITH WILD-TYPE RAS IN GREECE
Kourlaba, G.
Boukovinas, I
Saridaki, Z.
Papagiannopoulou, V
Tritaki, G.
Maniadakis, N.
VALUE IN HEALTH, 2014, 17 (07) : A633 - A633
[50] Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan plus Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer
Sobrero, Alberto
Lenz, Heinz-Josef
Eng, Cathy
Scheithauer, Werner
Middleton, Gary
Chen, Wenfeng
Esser, Regina
Nippgen, Johannes
Burris, Howard
ONCOLOGIST, 2021, 26 (02): : E261 - E269

← 1 2 3 4 5 →